CN116194472A - 癌症或肿瘤的治疗方法 - Google Patents

癌症或肿瘤的治疗方法 Download PDF

Info

Publication number
CN116194472A
CN116194472A CN202180060911.1A CN202180060911A CN116194472A CN 116194472 A CN116194472 A CN 116194472A CN 202180060911 A CN202180060911 A CN 202180060911A CN 116194472 A CN116194472 A CN 116194472A
Authority
CN
China
Prior art keywords
cancer
seq
tumor
cells
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180060911.1A
Other languages
English (en)
Chinese (zh)
Inventor
M·E·达德利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adaptimmune Ltd
Original Assignee
Adaptimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptimmune Ltd filed Critical Adaptimmune Ltd
Publication of CN116194472A publication Critical patent/CN116194472A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/51—Stomach
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180060911.1A 2020-05-13 2021-05-13 癌症或肿瘤的治疗方法 Pending CN116194472A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063024104P 2020-05-13 2020-05-13
US63/024,104 2020-05-13
PCT/GB2021/051158 WO2021229235A1 (en) 2020-05-13 2021-05-13 Method of treatment of cancer or tumour

Publications (1)

Publication Number Publication Date
CN116194472A true CN116194472A (zh) 2023-05-30

Family

ID=76098971

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180060911.1A Pending CN116194472A (zh) 2020-05-13 2021-05-13 癌症或肿瘤的治疗方法

Country Status (7)

Country Link
US (1) US20230190802A1 (enExample)
EP (1) EP4149631A1 (enExample)
JP (1) JP2023526259A (enExample)
CN (1) CN116194472A (enExample)
AU (1) AU2021270378A1 (enExample)
CA (1) CA3178588A1 (enExample)
WO (1) WO2021229235A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120594199A (zh) * 2025-08-06 2025-09-05 浙江省肿瘤医院 Mhc-ii表达在胃癌免疫治疗疗效预测中的用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
EP4304726A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Mage-a4 peptide-mhc antigen binding proteins
GB202205572D0 (en) * 2022-04-14 2022-06-01 Adaptimmune Ltd Engineered T cells
CN116449016A (zh) * 2022-08-26 2023-07-18 成都益安博生物技术有限公司 一种食管癌的外周血tcr标志物序列及其检测试剂盒和应用
GB202213050D0 (en) * 2022-09-07 2022-10-19 Adaptimmune Ltd Method of treatment of gastroesophageal cancer
EP4587046A1 (en) 2022-09-14 2025-07-23 CDR-Life AG Mage-a4 peptide dual t cell engagers
WO2024163440A1 (en) * 2023-01-31 2024-08-08 Agilent Technologies, Inc. Immunohistochemistry (ihc) mage-a4 scoring protocols and methods for aiding cancer treatments

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201616238D0 (en) * 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
AU2018234830B2 (en) * 2017-03-15 2023-03-02 Fred Hutchinson Cancer Center High affinity MAGE-A1-specific TCRs and uses thereof
US20210317184A1 (en) * 2018-09-05 2021-10-14 GlaxoSmithKline Intellectual Property Devolopment Limited T cell modification
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
GB2613715B (en) * 2019-02-20 2023-12-06 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
AU2021208433A1 (en) * 2020-01-14 2022-07-14 Uswm Ct, Llc Method of treatment of cancer or tumour

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D.S. HONG等: "Initial safety assessment of MAGE-A4 SPEAR T-cells", ANNALS OF ONCOLOGY, vol. 29, 31 October 2018 (2018-10-31) *
JOSEPH P SANDERSON等: "Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy", ONCOIMMUNOLOGY, vol. 9, no. 1, 24 November 2019 (2019-11-24), pages 1 - 2 *
VICTORIA E. ANDERSON等: "Enhanced Activity of Second-Generation MAGE-A4 SPEAR T-Cells Through Co-Expression of a CD8α Homodimer", IMMUNOLOGY, vol. 79, no. 13, 1 July 2019 (2019-07-01) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120594199A (zh) * 2025-08-06 2025-09-05 浙江省肿瘤医院 Mhc-ii表达在胃癌免疫治疗疗效预测中的用途

Also Published As

Publication number Publication date
CA3178588A1 (en) 2021-11-18
US20230190802A1 (en) 2023-06-22
AU2021270378A1 (en) 2022-12-15
EP4149631A1 (en) 2023-03-22
WO2021229235A1 (en) 2021-11-18
JP2023526259A (ja) 2023-06-21

Similar Documents

Publication Publication Date Title
Yu et al. Advances on immunotherapy for osteosarcoma
US20230190802A1 (en) Method of treatment of cancer or tumour
Barr et al. Recent advances and remaining challenges in lung cancer therapy
De Martino et al. Activin A promotes regulatory T-cell–mediated immunosuppression in irradiated breast cancer
CN116264826A (zh) 癌症或肿瘤的治疗方法
Rivera Vargas et al. Can immunogenic chemotherapies relieve cancer cell resistance to immune checkpoint inhibitors?
Yuan et al. Immunotherapies catering to the unmet medical need of cold colorectal cancer
US20220370559A1 (en) Method of treatment of cancer or tumour
Sanmamed et al. Overview of lung cancer immunotherapy
JP2024513915A (ja) 二重特異性ｔ細胞エンゲージャーの投与方法
US20230390334A1 (en) Method of treatment of cancer or tumour
US20260069692A1 (en) Modified t-cells for use in the treatment of gastroesophageal cancer
JP2025530188A (ja) 膀胱がんの治療において使用するための改変ｔ細胞
Moehler et al. Immune Strategies for Gastrointestinal Cancer
Aspeslagh et al. Development of Immunotherapeutic Strategies for Early Phase Clinical Trials
Moreno et al. Uzatresgene autoleucel autologous T-cell monotherapy for advanced solid tumors: SURPASS, a phase 1, open-label trial
JP2025530187A (ja) 頭頚部がんの治療において使用するための改変ｔ細胞
Callata-Carhuapoma et al. Immunological Treatment in Gastrointestinal Cancers
CA3252728A1 (en) DOSAGE REGIMEN FOR TCR-MODIFIED T-LYMPHOCYTE POLYTHERAPY IN COMBINATION WITH A PD-1 AXIS-BINDING ANTAGONIST
WO2022087230A1 (en) Cd4+ tfh-like cells as a therapeutic target
Taitt et al. Let us know how access to this document benefits yo u

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination